دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 4,800,000 تومان- قیمت ویژه : 2,400,000تومان
پکیج دسترسی ۳ ماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 93 ﺭﻭﺯ
قیمت : 1,500,000 تومان- قیمت ویژه : 750,000تومان
The Conundrum of Intermediate Risk in Localised Prostate Cancer: One Group, Many Realities
A Paradox of Our Time: Evidence-based Guidelines are Blocking Evidence-based Artificial Intelligence
Risk of Upgrading at Final Pathology after Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted Prostate Biopsies: A Post Hoc Analysis of the PERFECT Trial
Utility of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Detecting Lymph Node Involvement in Comparison to Conventional Imaging in Patients with Bladder Cancer with Variant Histology
Presence of an Artificial Intelligence–powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non–muscle-invasive Bladder Cancer
Repeat Prostate Cancer Screening using Blood-based Risk Prediction or Prostate-specific Antigen in the Era of Magnetic Resonance Imaging–guided Biopsies : A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial
Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial
Oncological Safety and Diagnostic Yield of Percutaneous Needle-core Biopsies in Upper Tract Urothelial Carcinoma: The UPERCUT Study
Bladder Cancer with Undetectable Circulating Tumor DNA After Radical Cystectomy May Be Amenable to a Less Intense Imaging Surveillance Protocol: A Diagnostic Accuracy Study
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience
Robotic Versus Open Radical Prostatectomy, Differences in Prostate Cancer–specific Survival—12 Years of Follow-up in the LAParoscopic Prostatectomy Robot Open Trial
Global Trends in the Incidence, Mortality, and Risk-attributable Deaths for Prostate, Bladder, and Kidney Cancers: A Systematic Analysis from the Global Burden of Disease Study 2021
The Burden of Genitourinary Malignancies in Southeast Asia from 1990 to 2021
Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced/Metastatic Urothelial Cancer and Non–muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study
Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma—An Observational Prospective Multicentre Diagnostic Test Cohort Study
MicroRNA as a Liquid Biomarker to Detect Malignancy in Small Testicular Masses
Impact of Implementation of Risk Calculators for the Selection of Extended Pelvic Lymph Node Dissection Candidates: 20-year Experience from a Tertiary Referral Centre
Efficacy of [177Lu]Lu-PSMA-617 in Patients with Metastatic Clear-cell Renal Cell Carcinoma: The Multicentre, Single-arm, Phase 2 RENALUT Trial
The Impact of Kidney, Liver, and Immune Function on Circulating Tumor DNA Detection in Muscle-invasive Bladder Cancer
Endoscopic Thulium Laser Ablation with Disitamab Vedotin and Immunotherapy in High-risk Upper Tract Urothelial Carcinoma: A Prospective Pilot Study of a Novel Kidney-sparing Strategy
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations—Genomic Features Associated with Response to Therapy
Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade Samples
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone–releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial
Downstream Impact of Social Media Use and Variable Quality of Online Information About Prostate Cancer
Outcomes of Focal Therapy for Localized Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies
Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis
Intermediate-risk Non–muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group
Systematic Review of the Definition of Cure and of Curative-intent Treatments in Early Bladder Cancer
Re: Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park, et al. Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab plus Olaparib Versus Abiraterone or Enzalutamide. EurUrol Oncol. In press. 10.1016/j.euo.2025.04.018
Re: Matthew J. Roberts, Philip Cornford, Derya Tilki. Oncological Benefits of Extended Pelvic Lymph Node Dissection: More Fog or Clarity to the Debate? Eur Urol. In press. 10.1016/j.eururo.2024.12.001
Pretreatment Predictors of Pathologic Failure at 1 year After Focal Therapy for Localized Prostate Cancer
Re: Himanshu Nagar, Marshall A. Diven, Brady Rippon, et al. A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution. Eur Urol Oncol. In press. 10.1016/j.euo.2025.05.014
